Glenn R Pilkington

Title: Glenn R. Pilkington: Innovator in Monoclonal Antibody Research

Introduction

Glenn R. Pilkington is a notable inventor based in Bethesda, MD, who has made significant contributions to the field of biomedical research. He holds two patents that focus on the development of neutralizing monoclonal antibodies for the treatment of respiratory syncytial virus (RSV). His work has the potential to impact therapeutic approaches for viral infections.

Latest Patents

Pilkington's latest patents revolve around the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The inventions provide antibodies, fragments of these antibodies that retain RSV-binding ability, and chimeric antibodies with similar properties. Additionally, the patents include pharmaceutical compositions that incorporate these antibodies, as well as isolated nucleic acids encoding the antibodies and host cells transformed with them. The inventions also outline diagnostic and therapeutic methods that utilize the antibodies and nucleic acids.

Career Highlights

Glenn R. Pilkington is associated with Intracel Resources LLC, where he continues to advance his research in monoclonal antibodies. His work is pivotal in the ongoing efforts to develop effective treatments for RSV, a virus that poses significant health risks, especially to infants and the elderly.

Collaborations

Some of his notable coworkers include Page S. Gilmour and Robert M. Chanock, who have collaborated with him on various research projects. Their combined expertise contributes to the innovative approaches being developed in the field of virology.

Conclusion

Glenn R. Pilkington's contributions to the field of monoclonal antibody research highlight his role as an influential inventor. His patents on neutralizing antibodies for respiratory syncytial virus represent significant advancements in therapeutic options for viral infections.